Matrixyl half-life & pharmacokinetics

Reported half-life

Not systemically pharmacokinetically relevant given the topical cosmetic use case. Percutaneous absorption to dermal fibroblasts is the pharmacokinetic parameter of interest, enabled by the palmitoyl fatty acid modification that facilitates crossing the stratum corneum lipid barrier. Effective dermal residence time depends on formulation vehicle and skin barrier condition.

The half-life and pharmacokinetic profile of Matrixyl reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Topical application (cosmetic and research standard route)
• Intradermal injection (research protocols only)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Palmitoylated pentapeptide cosmetic ingredient derived from type-I procollagen propeptide sequence; dermal fibroblast collagen-synthesis stimulator; legal INCI-listed cosmetic ingredient in the UK.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Matrixyl acts as follows:

Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS) is a synthetic cosmetic peptide developed by Sederma (now part of Croda International) as a topical dermal collagen-synthesis stimulator. The active pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser) is derived from the C-terminal propeptide sequence of the type-I procollagen α1 chain — the small peptide fragment generated when procollagen is processed to mature collagen by procollagen C-endopeptidase. The observation that this natural cleavage product produced feedback stimulation of collagen synthesis in dermal fibroblasts motivated its development as a cosmetic active. The palmitoyl (C16 fatty acid) N-terminal modification is essential for topical utility — the unmodified KTTKS pentapeptide has negligible skin penetration; palmitoylation enables percutaneous absorption through the stratum corneum lipid barrier while retaining the intrinsic collagen-stimulating activity of the pentapeptide.

See the full Matrixyl research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.